Identification of Tubocapsanolide A as a novel NLRP3 inhibitor for potential treatment of colitis

Volume: 190, Pages: 114645 - 114645
Published: Aug 1, 2021
Abstract
Increasing evidence have reported that NLRP3 inflammasome has a crucial role in various kinds of immunological diseases including colitis. However, there have only a few drug candidates directly targeting inflammasomes for the therapy of colitis. Here, we first reported that Tubocapsanolide A (TA), a natural small molecule, as a novel inhibitor of NLRP3 inflammasome for the treatment of colitis. TA inhibited the activation of NLRP3 inflammasome...
Paper Details
Title
Identification of Tubocapsanolide A as a novel NLRP3 inhibitor for potential treatment of colitis
Published Date
Aug 1, 2021
Volume
190
Pages
114645 - 114645
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.